Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- (“Jeune”), a wholly owned subsidiary of (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore’s healthcare group, where he advised on transactions totaling over $500 billion in aggregate value.

“It is my pleasure to welcome Nishant to the Jeune team,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech and Chairman of Jeune Aesthetics. “As a seasoned finance executive and cross-functional leader with deep capital markets and transactions experience, including in the field of medical aesthetics, Nishant is a great fit for Jeune as we advance our lead program into Phase 2 later this year. I look forward to working with Nishant to unlock the significant value we believe exists in our medical aesthetics pipeline.”

Mr. Saxena brings extensive experience in life sciences, capital markets, and finance to his role as CFO at Jeune. Prior to joining Jeune, Mr. Saxena was a Managing Director in the strategic advisory practice focused on the biopharmaceutical sector at Evercore. In his over 15 years at Evercore, Mr. Saxena led numerous client engagements and advised on mergers and acquisitions, private placements, initial public offerings, follow-on offerings, partnerships, structured financings, and other transactions. Earlier in his career, Mr. Saxena held positions of increasing responsibility in private equity, venture capital, and investment advisory firms. Mr. Saxena received a B.S. in Economics and an MBA from the Wharton School at the University of Pennsylvania.

“I am excited to be joining Jeune as the company embarks on its next stage of growth,” said Mr. Saxena. “With promising KB301 Phase 1 data and a growing, innovative pipeline following closely behind, Jeune is uniquely positioned to meet the strong existing demand for therapies that fundamentally address aged skin. I look forward to working with the talented team at Jeune to drive investment and build a leader in rejuvenative medical aesthetics.”

About KB301

KB301 is an investigational aesthetic therapy employing Krystal’s novel replication-defective, non-integrating HSV-1-based vector to deliver two copies of the COL3A1 transgene and increase COL3 levels in skin to address signs of skin aging associated with declining collagen levels and damage of the skin’s extracellular matrix. KB301 is formulated as a solution for direct intradermal injection to aesthetic priority areas.

About Jeune Aesthetics, Inc.

Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc., is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging skin. For more information, please visit .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK^® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit , and follow @KrystalBiotech on and (formerly Twitter).

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., or its wholly-owned subsidiary, Jeune Aesthetics, Inc., including statements about unlocking the significant value management believes exists in Jeune’s growing and innovative medical aesthetics pipeline; plans to progress Jeune’s lead product into Phase 2 development in 2025; driving investment in Jeune and building a leader in rejuvenative medical aesthetics; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties associated with regulatory review of clinical trials, the availability or commercial potential of Jeune’s investigative products, and such other important factors as are set forth under the caption “Risk Factors” in Krystal’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal’s and Jeune’s views as of the date of this press release. Krystal and Jeune anticipate that subsequent events and developments will cause their views to change. However, while Krystal and Jeune may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal’s and Jeune’s views as of any date subsequent to the date of this press release.

CONTACT

Investors and Media:                                                             

Stéphane Paquette, PhD                                                         

Krystal Biotech